Douglas E. Onsi - 17 Mar 2023 Form 4 Insider Report for LEAP THERAPEUTICS, INC. (LPTX)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
21 Mar 2023, 16:05:20 UTC
Prior SEC filing
02 Sep 2022
Next SEC filing
04 Apr 2023
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas E. Onsi

Key filing fact

Douglas E. Onsi filed Form 4 for LEAP THERAPEUTICS, INC. (LPTX) on 21 Mar 2023.

Key facts

  • This page summarizes Douglas E. Onsi's Form 4 filing for LEAP THERAPEUTICS, INC. (LPTX).
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 21 Mar 2023, 16:05.

Change

  • Previous filing in this sequence was filed on 02 Sep 2022.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

LPTX transaction

Common Stock

Options Exercise

Transaction value
Shares
+660,606
Change %
+76815%
Price
Shares after
661,466
Date
17 Mar 2023
Ownership
Direct
Footnotes
F1
LPTX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
4,144,804
Date
17 Mar 2023
Ownership
By HealthCare Ventures IX, L.P.
Footnotes
F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

LPTX transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
$0
Shares
-660,606
Change %
-100%
Price
$0.000000*
Shares after
0
Date
17 Mar 2023
Ownership
Direct
Underlying class
Common Stock
Underlying amount
660,606
Exercise price
Footnotes
F1, F3
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Restricted Stock Units convert into common stock on a one-for-one basis.

Footnote F2

The reporting person is a Managing Director of HealthCare Partners IX, LLC which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HealthCare Ventures IX, L.P. The reporting person beneficially owns and shares voting and dispositive power with respect to all of the securities owned by HealthCare Ventures IX, L.P. and disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein.

Footnote F3

On March 17, 2020, the reporting person was granted 660,606 Restricted Stock Units, vesting on March 17, 2023 or upon a change of control, whichever is earlier, provided that the grantee continues to be employed by, or provides service to the Company from the grant date to the vesting date of the Restricted Stock Units. At such time as the Restricted Stock Units vest, one share of Common Stock shall be issued automatically in settlement of each Restricted Stock Unit.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .